文献速递系统性红斑狼疮

难治性系统性红斑狼疮淋巴清除性自体造血细胞移植后的长期随访

Long-term follow-up after lymphodepleting autologous haematopoietic cell transplantation for treatment-resistant systemic lupus erythematosus.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

8例对静脉环磷酰胺等治疗难治的SLE患者接受淋巴清除性减低强度预处理自体造血细胞移植,5例达完全缓解(SLEDAI降至0),其中4例中位持续165个月;1例部分缓解后18个月复发;2例合并肾炎及多器官基础病者早期死于感染和多器官衰竭。

要点

  • 8例难治性SLE接受淋巴清除性AHSCT,5例完全缓解,4例中位持续165个月。
  • 完全缓解者IFN诱导基因特征持续抑制、记忆B细胞和浆母细胞显著耗竭、抗dsDNA抗体持续清除。
  • 2例合并肾炎及多器官基础病者早期死于感染和多器官衰竭。

核心结论

  • 难治性SLE经淋巴清除性AHSCT后可实现持久的临床和血清学缓解,并伴IFN基因特征抑制。

研究设计与样本

  • 单臂研究,纳入8例对治疗难治(包括静脉环磷酰胺)的SLE患者,其中5例以狼疮肾炎、3例以中枢神经系统受累为主要移植指征。
  • mobilization采用环磷酰胺、G-CSF和利妥昔单抗,随后采集CD34阳性选择细胞;预处理为环磷酰胺、氟达拉滨和利妥昔单抗同时给药。
  • 动员开始时停用所有免疫抑制药物,移植后快速减量糖皮质激素。

主要发现

  • 8例中5例达完全缓解,包括SLEDAI降至0,其中4例中位持续165个月(范围138-191)。
  • 1例达部分缓解,随后在第18个月复发。
  • 2例合并肾炎且多数器官存在基础合并症的患者早期死于感染和多器官衰竭。
  • AHSCT导致深度淋巴细胞清除,随后Treg细胞扩增及初始T细胞和B细胞重建。
  • 完全缓解者显示SLE相关IFN诱导基因特征持续抑制、记忆B细胞和浆母细胞显著耗竭及抗dsDNA抗体持续清除。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Autologous haematopoietic cell transplantation (AHSCT) improves immunologic dysfunction in patients with SLE. However, the curative potential of this therapy remains uncertain. This study reports outcomes in SLE patients receiving a lymphodepleting, reduced intensity regimen for AHSCT in SLE. METHODS: Eight patients with SLE refractory to treatment, including i.v. cyclophosphamide (CYC), were enrolled. Five had LN and three CNS involvement as primary indications for transplant. Haematopoietic cell mobilization with CYC, G-CSF and rituximab was followed by collection of CD34+ positively selected cells. The conditioning regimen consisted of concurrent administration of CYC, fludarabine and rituximab. All immunosuppressive medications were discontinued at the start of mobilization and CS were rapidly tapered after the transplant. RESULTS: Five of eight patients achieved a complete response, including a decline in the SLEDAI to zero, which was sustained in four patients for a median of 165 months (range 138-191). One patient achieved a partial response, which was followed by relapse at month 18. Two patients with nephritis and underlying comorbidities in most organs had early deaths from infection and multiorgan failure. AHSCT resulted in profound lymphodepletion, followed by expansion of Treg cells and repopulation of naive T and B cells. Patients with a complete response showed a sustained suppression of the SLE-associated IFN-induced gene signature, marked depletion of memory and plasmablast B cells and resultant sustained elimination of anti-dsDNA antibody. CONCLUSION: Durable clinical and serologic remissions with suppression in the IFN gene signature can be achieved in refractory SLE following lymphodepleting AHSCT. TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov, NCT00076752.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Goklemez S, Hasni S, Hakim FT, et al. Long-term follow-up after lymphodepleting autologous haematopoietic cell transplantation for treatment-resistant systemic lupus erythematosus. Rheumatology (Oxford). 2022. PMID: 34875023. doi:10.1093/rheumatology/keab877

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。